Tvardi Therapeutics (NASDAQ:TVRD) Downgraded by Wall Street Zen to Sell

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Friday.

A number of other research firms also recently issued reports on TVRD. BTIG Research reduced their price target on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating for the company in a research report on Monday, October 13th. Barclays set a $5.00 target price on shares of Tvardi Therapeutics and gave the company an “equal weight” rating in a research report on Monday, October 13th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Tvardi Therapeutics in a report on Monday, December 29th. Raymond James Financial downgraded shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 14th. Finally, Cantor Fitzgerald downgraded shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Tvardi Therapeutics has an average rating of “Hold” and a consensus target price of $55.50.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ TVRD traded down $0.14 during midday trading on Friday, hitting $4.69. 29,407 shares of the stock traded hands, compared to its average volume of 123,356. The firm has a 50-day moving average of $4.21 and a two-hundred day moving average of $16.81. The firm has a market capitalization of $43.99 million, a P/E ratio of -0.49 and a beta of 0.09. Tvardi Therapeutics has a one year low of $3.74 and a one year high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.24.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Vestal Point Capital LP purchased a new stake in Tvardi Therapeutics in the 3rd quarter worth $6,508,000. Parkman Healthcare Partners LLC bought a new position in shares of Tvardi Therapeutics in the third quarter worth about $2,533,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Tvardi Therapeutics in the third quarter worth about $746,000. Squarepoint Ops LLC purchased a new stake in shares of Tvardi Therapeutics during the third quarter worth about $318,000. Finally, Invesco Ltd. bought a new stake in Tvardi Therapeutics during the 3rd quarter valued at approximately $3,219,000. Institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.